Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 206 results for myocardial infarction

  1. Cardiovascular disease. Patient decision aid on should I take a statin?

    What are heart disease and stroke? Heart disease includes heart attacks and angina. Heart attacks happen when the blood...

  2. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

  3. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (HTG724)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

  4. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  5. E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (HTG326)

    Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.

  6. Sustainability

    NICE is committed to supporting the national agenda for achieving a sustainable health and care system.

  7. Type 2 diabetes in adults. Patient decision aid on type 2 diabetes: agreeing my blood glucose (HbA1c) target

    problems with their blood vessels and heart. These might include angina, a heart attack or a stroke. They also have an increased risk of...

  8. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

  9. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  10. NICE's strategic priorities in 2026 to 2027

    Over the next year, our prioritisation decisions will be shaped by the government’s strategic direction for health and life sciences, and by the needs of the NHS, local systems and the people who use services.

  11. How you can use our recommendations, tools and resources: cardiovascular disease

    How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).

  12. Cardiovascular disease prevention (PH25)

    This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.

  13. Cardiac rehabilitation:- Is an 8-week, comprehensive, multidisciplinary, cardiac rehabilitation service more clinically and cost effective for managing stable angina than current clinical practice?

    strategy for certain heart conditions, such as for people who have had a heart attack. However, there is no evidence to suggest that...

  14. Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock (HTG774)

    Evidence-based recommendations on surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock. This involves a small pump being surgically inserted using a graft, through an artery and into the heart, to temporarily pump blood out of the heart and restore blood flow.

  15. Acute heart failure (QS103)

    This quality standard covers the care of adults (aged 18 and over) with suspected or confirmed acute heart failure. It describes high-quality care in priority areas for improvement.